和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00013 和黄医药

交易中 07-23 14:57:53

29.850

-1.400

-4.48%

最高32.000	最低29.600	成交量411.25万
今开31.750	昨收31.250	日振幅7.68%
总市值260.10亿	流通市值260.10亿	总股本8.71亿
成交额1.25亿	换手率0.47%	流通股本8.71亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00013","market":"HK","secType":"STK","nameCN":"和黄医药","latestPrice":29.85,"timestamp":1721717862483,"preClose":31.25,"halted":0,"volume":4112500,"delay":0,"floatShares":871359720,"shares":871359720,"eps":0.9260341,"marketStatus":"交易中","marketStatusCode":2,"change":-1.4,"latestTime":"07-23 14:57:53","open":31.75,"high":32,"low":29.6,"amount":124557476,"amplitude":0.0768,"askPrice":29.85,"askSize":9000,"bidPrice":29.75,"bidSize":7500,"shortable":3,"etf":0,"ttmEps":0.9260340708586418,"exchange":"SEHK","tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1721722200000},"adr":0,"listingDate":1624982400000,"adjPreClose":31.25,"openAndCloseTimeList":[[1721698200000,1721707200000],[1721710800000,1721721600000]],"volumeRatio":1.487725,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00013","defaultTab":"news","newsList":[{"id":"2453705355","title":"和黄医药(00013)下跌5.12%，报29.65元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2453705355","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453705355?lang=zh_cn&edition=full","pubTime":"2024-07-23 14:39","pubTimestamp":1721716791,"startTime":"0","endTime":"0","summary":"7月23日，和黄医药(00013)盘中下跌5.12%，截至14:39，报29.65元/股，成交1.2亿元。和黄医药(中国)有限公司是一家专注于全球市场的创新型医药研发企业，主要业务包括研发、生产、营销和经销抗肿瘤药物、处方药和消费保健产品。公司在全球范围内拥有多个上市药物，并在纳斯达克全球精选市场、香港交易所以及伦敦证交所的AIM市场上市。截至2023年年报，和黄医药营业总收入59.35亿元、净利润7.14亿元。7月31日，和黄医药将披露2024财年中报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/23143941729818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4007","BK1587","BK4588","00013","BK1588","BK4585","BK1191","BK4531","HCM"],"gpt_icon":0},{"id":"2453703156","title":"和黄医药盘中异动 下午盘股价大跌5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2453703156","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453703156?lang=zh_cn&edition=full","pubTime":"2024-07-23 14:39","pubTimestamp":1721716785,"startTime":"0","endTime":"0","summary":"2024年07月23日下午盘14时39分，和黄医药股票出现异动，股价大幅下跌5.12%。截至发稿，该股报29.650港元/股，成交量397.5万股，换手率0.46%，振幅7.52%。资金方面，该股资金流入4774.62万港元，流出5244.79万港元。和黄医药股票所在的药品行业中，整体跌幅为0.40%。其相关个股中，中智药业、培力农本方、亿胜生物科技涨幅较大，振幅较大的相关个股有泰凌医药(旧)、中生联合、和黄医药，振幅分别为28.12%、14.12%、7.36%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240723143945aefaeb15&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240723143945aefaeb15&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","00013","BK1588","BK1587"],"gpt_icon":0},{"id":"2453782668","title":"和黄医药早盘涨近6% 东北证券维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2453782668","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453782668?lang=zh_cn&edition=full","pubTime":"2024-07-22 11:42","pubTimestamp":1721619748,"startTime":"0","endTime":"0","summary":"和黄医药（00013）早盘涨幅持续扩大，股价上涨5.74%，现报31.30港元，成交额7210.32万港元。\n　　东北证券研报指，公司近期研发进展迅速，多产品同步发力，展现了优异的临床数据和竞争格局，并不断推进产品全球化，预计将持续催化公司基本面价值提升。另外，公司管线储备丰富，产品市场空间广阔，不断实现海外放量。东北证券维持和黄医药“买入”评级。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-07-22/doc-inceypaf4759362.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-07-22/doc-inceypaf4759362.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["00013"],"gpt_icon":0},{"id":"2453789532","title":"港股异动 | 和黄医药(00013)再涨超5% 公司近期介绍创新药物进展 机构称研发进展迅速","url":"https://stock-news.laohu8.com/highlight/detail?id=2453789532","media":"智通财经","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2453789532?lang=zh_cn&edition=full","pubTime":"2024-07-22 10:42","pubTimestamp":1721616141,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和黄医药(00013)再涨超5%，截至发稿，涨5.41%，报31.2港元，成交额4428.23万港元。消息面上，7月9日，和黄医药举办2024年研发日交流活动，公司管理层在会议中重点分享了候选创新管线的临床数据与市场价值，包括索乐匹尼布在自身免疫性疾病的临床数据及优势分析、索凡替尼在胰腺癌的治疗潜力、HMPL-306用于治疗急性髓系白血病的早期数据分析及III期临床设计。东北证券指出，公司近期研发进展迅速，多产品同步发力，展现了优异的临床数据和竞争格局，并不断推进产品全球化，预计将持续催化公司基本面价值提升。另外，公司管线储备丰富，产品市场空间广阔，不断实现海外放量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153739.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00013","BK1161","159992","BK4585","BK1191","BK1574","BK1587","HCM","HSCEI","BK4007","HSTECH","BK4588","06978","YANG","BK4531","BK1588"],"gpt_icon":1},{"id":"2453789273","title":"和黄医药(00013)上涨5.07%，报31.1元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2453789273","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453789273?lang=zh_cn&edition=full","pubTime":"2024-07-22 10:35","pubTimestamp":1721615716,"startTime":"0","endTime":"0","summary":"7月22日，和黄医药(00013)盘中上涨5.07%，截至10:35，报31.1元/股，成交3959.27万元。和黄医药(中国)有限公司是一家专注于全球市场的创新型医药研发企业，主要业务包括研发、生产、营销和经销抗肿瘤药物、处方药和消费保健产品。公司在全球范围内拥有多个上市药物，并在纳斯达克全球精选市场、香港交易所以及伦敦证交所的AIM市场上市。截至2023年年报，和黄医药营业总收入59.35亿元、净利润7.14亿元。7月31日，和黄医药将披露2024财年中报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/22103541702057.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["HCM","00013","BK4007","BK4531","BK1191","BK4588","BK4585","BK1588","BK1587"],"gpt_icon":0},{"id":"2453891957","title":"和黄医药盘中异动 股价大涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2453891957","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453891957?lang=zh_cn&edition=full","pubTime":"2024-07-22 10:35","pubTimestamp":1721615712,"startTime":"0","endTime":"0","summary":"2024年07月22日早盘10时35分，和黄医药股票出现异动，股价大幅拉升5.07%。截至发稿，该股报31.101港元/股，成交量130.05万股，换手率0.15%，振幅4.73%。和黄医药股票所在的药品行业中，整体涨幅为0.21%。其相关个股中，中生联合、康龙化成、和黄医药涨幅较大，振幅较大的相关个股有中生联合、联康生物科技集团、开拓药业-B，振幅分别为20.78%、16.95%、6.80%。和黄医药公司简介：和黄医药(中国)有限公司是一间主要从事制造及销售药物的投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240722103512af935648&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240722103512af935648&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","BK1191","BK1587","00013"],"gpt_icon":0},{"id":"2453789118","title":"和黄医药(00013)股价上升5.068%，现价港币$31.1","url":"https://stock-news.laohu8.com/highlight/detail?id=2453789118","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453789118?lang=zh_cn&edition=full","pubTime":"2024-07-22 10:35","pubTimestamp":1721615700,"startTime":"0","endTime":"0","summary":"[上升股]和黄医药(00013) 股价在上午10:35比前收市价上升5.068%，现股价为港币$31.1。至目前为止，今日最高价为$31.1，而最低价为$29.7。总成交量为129.95万股，总成交金额为港币$3.947千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190515141041255_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190515141041255_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR240722829/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1588","BK1191","00013","BK1587"],"gpt_icon":0},{"id":"2452417174","title":"和黄医药07月18日遭主力抛售676万元 环比增加347.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452417174","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452417174?lang=zh_cn&edition=full","pubTime":"2024-07-18 16:16","pubTimestamp":1721290594,"startTime":"0","endTime":"0","summary":"07月18日, 和黄医药股价涨1.50%，报收30.55元，成交金额6525万元，换手率0.25%，振幅2.66%，量比0.44。和黄医药今日主力资金净流出676万元，上一交易日主力净流出151万元，今日环比增加347.68%。该股近5个交易日上涨10.81%，主力资金累计净流入2466万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入4021万元，其中净流入天数为10日。该股主力净额占比0.03%，港股市场排名2587/2648。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407181616459f62dc94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407181616459f62dc94&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1587","00013","BK1588"],"gpt_icon":0},{"id":"2452902499","title":"【港股通】和黄医药(00013)涨3.24% 华源证券指其创新产品管线丰富 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2452902499","media":"金吾资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452902499?lang=zh_cn&edition=full","pubTime":"2024-07-17 13:42","pubTimestamp":1721194949,"startTime":"0","endTime":"0","summary":"金吾财讯 | 和黄医药(00013)股价震荡上行，截至发稿，涨3.24%，报30.25港元，成交额7988.85万港元。华源证券发研指，公司创新产品管线丰富，全球化进展顺利，维持公司“买入”评级。公司指引2024年肿瘤/免疫业务综合收入为3.0 亿至4.0 亿美元（得益于已上市的肿瘤产品销售额及特许权使用费30%-50%的目标增长）。此外，截至23年末，公司在手现金8.86亿美元。该行预计2024-2026 年，公司总收入为7.05、9.12、11.85 亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407171342449f5b4a38&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407171342449f5b4a38&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HSCEI","00013","HSTECH"],"gpt_icon":1},{"id":"2451981316","title":"南向资金7月15日净买入和黄医药126.05万股 连续5日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2451981316","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451981316?lang=zh_cn&edition=full","pubTime":"2024-07-16 09:31","pubTimestamp":1721093488,"startTime":"0","endTime":"0","summary":"7月15日, 南向资金增持和黄医药126.05万股，连续5日增持。截止当日收盘，港股通共持有和黄医药15557.54万股，占流通股17.84%。和黄医药近5个交易日上涨11.75%，港股通累计增持378.50万股；近20个交易日上涨4.17%，港股通累计增持451.66万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071609383695c43818&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071609383695c43818&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00013","BK4588","HCM","BK4007","BK4531","BK4585"],"gpt_icon":0},{"id":"2450532775","title":"美股异动 | 东北证券维持“买入”评级 和黄医药(HCM.US)涨超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450532775","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450532775?lang=zh_cn&edition=full","pubTime":"2024-07-12 22:56","pubTimestamp":1720796173,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周五，和黄医药(HCM.US)股价走高，截至发稿，该股涨超8%，报19.245美元，港股今日收涨逾7%。东北证券研报指，公司近期研发进展迅速，多产品同步发力，展现了优异的临床数据和竞争格局，并不断推进产品全球化，预计将持续催化公司基本面价值提升。另外，公司管线储备丰富，产品市场空间广阔，不断实现海外放量。东北证券维持和黄医药“买入”评级。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1150484.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["HCM","000686","00013"],"gpt_icon":0},{"id":"2450399135","title":"和黄医药(HCM)升近7% 机构指公司产品近期临床数据优异 料将持续催化公司基本面价值提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2450399135","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450399135?lang=zh_cn&edition=full","pubTime":"2024-07-12 22:12","pubTimestamp":1720793523,"startTime":"0","endTime":"0","summary":"金吾财讯 | 和黄医药(HCM)早盘股价震荡走高，截至发稿，涨6.88%，报19.003美元，成交额116.36万美元。交银国际发布研究报告称，维持和黄医药“买入”评级，目标价40港元。索凡替尼联合PD-1一线治疗胰腺癌疗效令人鼓舞，ASCO GI大会上公表的一项IIT数据显示，索凡替尼联合AS疗法和卡瑞利珠单抗治疗1L PDAC的ORR达50%，mPFS/mOS分别为9及13.3个月，明显优于现有疗法。东北证券表示，公司近期研发进展迅速，多产品同步发力，展现了优异的临床数据和竞争格局，并不断推进产品全球化，预计将持续催化公司基本面价值提升。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/NGU1YzNhMmY0MDcxNDc2NDI4MDI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGU1YzNhMmY0MDcxNDc2NDI4MDI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"277733","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCM","BK4588","BK1191","BK4007","BK4531","BK1588","00013","BK1587","BK4585"],"gpt_icon":0},{"id":"2450309402","title":"和黄医药(HCM)盘前涨逾4% 东北证券维持公司“买入”评级 指其管线储备丰富","url":"https://stock-news.laohu8.com/highlight/detail?id=2450309402","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450309402?lang=zh_cn&edition=full","pubTime":"2024-07-12 17:19","pubTimestamp":1720775981,"startTime":"0","endTime":"0","summary":"金吾财讯 | 和黄医药(HCM)美股盘前走高，暂升4.05%，报18.5美元。今日港股和黄医药(00013)收涨7.21%，报29.75港元，成交额2.12亿港元。东北证券发研指，公司近期研发进展迅速，多产品同步发力，展现了优异的临床数据和竞争格局，并不断推进产品全球化，预计将持续催化公司基本面价值提升。公司管线储备丰富，产品市场空间广阔，不断实现海外放量。该行预计公司24-26年实现收入7.29/8.66/10.00亿美元，每股收益为-0.06/0.05/0.18美元，维持公司“买入”评级。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/OTg4YTUxMDE3ODY5MDkyNDI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/OTg4YTUxMDE3ODY5MDkyNDI=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"277704","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCM","000686","00013"],"gpt_icon":0},{"id":"2450306647","title":"美股异动 | 券商唱好 和黄医药盘前涨4% H股今日大幅收涨超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450306647","media":"市场资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450306647?lang=zh_cn&edition=full","pubTime":"2024-07-12 16:56","pubTimestamp":1720774560,"startTime":"0","endTime":"0","summary":"格隆汇7月12日｜港股和黄医药收涨逾7%，带动和黄医药(HCM.US)美股盘前涨4%，报8.5美元。东北证券研报指，公司近期研发进展迅速，多产品同步发力，展现了优异的临床数据和竞争格局，并不断推进产品全球化，预计将持续催化公司基本面价值提升。另外，公司管线储备丰富，产品市场空间广阔，不断实现海外放量。维持公司“买入”评级。\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：郭明煜","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/bxjj/2024-07-12/doc-inccwkrv4545109.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2024-07-12/doc-inccwkrv4545109.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1587","BK4588","BK4531","BK4007","BK4585","BK1588","BK1191","HCM","00013"],"gpt_icon":0},{"id":"2450376574","title":"【券商聚焦】东北证券维持和黄医药(00013)“买入”评级 料公司产品全球化将持续催化公司基本面价值提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2450376574","media":"金吾资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450376574?lang=zh_cn&edition=full","pubTime":"2024-07-12 14:27","pubTimestamp":1720765647,"startTime":"0","endTime":"0","summary":"金吾财讯 | 东北证券发研报指，和黄医药(00013)在上海举办会议分享最新研发进展，并通过网络同步直播。公司高级管理团队于会议中分享了公司的研发策略和愿景，以及公司丰富且创新的候选药物管线中的部分项目，包括索凡替尼、索乐匹尼布以及HMPL-306等产品的最新进展。该行续指，公司近期研发进展迅速，多产品同步发力，展现了优异的临床数据和竞争格局，并不断推进产品全球化，预计将持续催化公司基本面价值提升。公司管线储备丰富，产品市场空间广阔，不断实现海外放量。该行预计公司24-26年实现收入7.29/8.66/10.00亿美元，每股收益为-0.06/0.05/0.18美元，维持公司“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071214273795ab6bf5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071214273795ab6bf5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00013"],"gpt_icon":0},{"id":"2450326087","title":"和黄医药早盘涨超6% 交银国际指公司下半年有多项催化剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2450326087","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450326087?lang=zh_cn&edition=full","pubTime":"2024-07-12 11:34","pubTimestamp":1720755262,"startTime":"0","endTime":"0","summary":"和黄医药（00013）早盘曾涨超9%，截至发稿，股价上涨6.49%，现报29.55港元，成交额1.33亿港元。\n　　交银国际指出，索凡替尼联合PD-1一线治疗胰腺癌疗效令人鼓舞，ASCO GI大会上公表的一项IIT数据显示，索凡替尼联合AS疗法和卡瑞利珠单抗治疗1L PDAC 的ORR 达50%，mPFS/mOS分别为9及13.3个月，明显优于现有疗法。公司2024年下半年催化剂包括呋喹替尼第二季全球销售和基于FRUTIGA研究的2L胃癌国内审批进展；赛沃替尼基于SAVANNAH研究的全球申报；索乐匹尼布国内核准。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-07-12/doc-inccvxzz4643952.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-07-12/doc-inccvxzz4643952.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1147","BK1587","00013","03329","BK1191","BK1588"],"gpt_icon":0},{"id":"2450323397","title":"港股异动 | 和黄医药(00013)再涨超9% 公司近期分享最新管线进展 机构称下半年有多项催化剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2450323397","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450323397?lang=zh_cn&edition=full","pubTime":"2024-07-12 10:45","pubTimestamp":1720752312,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和黄医药再涨超9%，截至发稿，涨7.03%，报29.7港元，成交额1.14亿港元。公司2024年下半年催化剂包括呋喹替尼第二季全球销售和基于FRUTIGA研究的2L胃癌国内审批进展；赛沃替尼基于SAVANNAH研究的全球申报；索乐匹尼布国内核准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1149823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4007","BK1587","HSCEI","07226","YANG","BK4588","00013","BK1588","HSTECH","BK4585","BK1191","BK4531","HCM"],"gpt_icon":0},{"id":"2450134234","title":"和黄医药盘中异动 快速拉升5.05%报29.150港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450134234","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450134234?lang=zh_cn&edition=full","pubTime":"2024-07-12 09:31","pubTimestamp":1720747880,"startTime":"0","endTime":"0","summary":"截至发稿，该股报29.150港元/股，成交量43.25万股，换手率0.05%，振幅3.24%。机构评级方面，在所有17家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。和黄医药股票所在的药品行业中，整体涨幅为0.03%。其相关个股中，和黄医药、康臣药业、凯莱英涨幅较大，振幅较大的相关个股有顺腾国际控股、和黄医药、翰森制药，振幅分别为12.20%、3.06%、2.75%。该信息摘要如下：交银国际发布研究报告称，维持和黄医药“买入”评级，目标价40港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240712093120af91f2de&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240712093120af91f2de&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00013","BK1587","BK1191","BK1588"],"gpt_icon":0},{"id":"2450806799","title":"和黄医药早盘涨近4% 交银国际维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2450806799","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450806799?lang=zh_cn&edition=full","pubTime":"2024-07-11 11:54","pubTimestamp":1720670085,"startTime":"0","endTime":"0","summary":"和黄医药（00013）早盘上涨3.70%，现报28港元，成交额9389.40万港元。\n　　交银国际发布研究报告称，维持和黄医药“买入”评级，目标价40港元。报告中称，公司2024年下半年催化剂包括呋喹替尼第二季全球销售和基于FRUTIGA研究的2L胃癌国内审批进展；赛沃替尼基于SAVANNAH研究的全球申报；索乐匹尼布国内核准。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-07-11/doc-incctqvh8765569.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-07-11/doc-incctqvh8765569.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["00013"],"gpt_icon":0},{"id":"2450051248","title":"港股异动 | 和黄医药(00013)涨超4% 公司下半年包含呋喹替尼第二季全球销售在内等多项催化剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2450051248","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450051248?lang=zh_cn&edition=full","pubTime":"2024-07-11 11:26","pubTimestamp":1720668388,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和黄医药(00013)涨超4%，截至发稿，涨4.26%，报28.15港元，成交额8556.34万港元。交银国际发布研究报告称，维持和黄医药“买入”评级，目标价40港元。报告中称，公司2024年下半年催化剂包括呋喹替尼第二季全球销售和基于FRUTIGA研究的2L胃癌国内审批进展；赛沃替尼基于SAVANNAH研究的全球申报；索乐匹尼布国内核准。该行指出，索凡替尼联合PD-1一线治疗胰腺癌疗效令人鼓舞，ASCO GI大会上公表的一项IIT数据显示，索凡替尼联合AS疗法和卡瑞利珠单抗治疗1L PDAC的ORR达50%，mPFS/mOS分别为9及13.3个月，明显优于现有疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1149188.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4531","YANG","BK1191","HSTECH","BK1587","BK4007","HSCEI","HCM","07226","00013","BK4585","BK4588","BK1588"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hutch-med.com","stockEarnings":[{"period":"1week","weight":0.0434},{"period":"1month","weight":0.1082},{"period":"3month","weight":0.1023},{"period":"6month","weight":0.4603},{"period":"1year","weight":0.547},{"period":"ytd","weight":0.0889}],"compareEarnings":[{"period":"1week","weight":-0.0211},{"period":"1month","weight":-0.0218},{"period":"3month","weight":0.048},{"period":"6month","weight":0.1092},{"period":"1year","weight":-0.0755},{"period":"ytd","weight":0.0345}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和黄医药（中国）有限公司（原名：和黄中国医药科技有限公司）是一家主要从事药品制造及销售的投资控股公司。连同其附属公司，该公司通过两个分部经营业务。肿瘤及免疫业务分部从事发现、开发和商业化用于治疗癌症和免疫性疾病的靶向疗法和免疫疗法，包括涵盖药物发现、开发、生产及监管职能的研发活动，以及支持研发业务的行政活动，还包括通过研发活动开发的药物的销售、推广、生产及分销。其他业务分部从事其他商业化业务，包括其他处方药物及非处方药物以及消费保健品的销售、推广、生产及分销。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.130873},{"month":2,"riseRate":0.666667,"avgChangeRate":0.058734},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.131658},{"month":4,"riseRate":0.666667,"avgChangeRate":0.04977},{"month":5,"riseRate":0,"avgChangeRate":-0.194502},{"month":6,"riseRate":0.333333,"avgChangeRate":0.018958},{"month":7,"riseRate":1,"avgChangeRate":0.14508},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.046428},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.081182},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.003665},{"month":11,"riseRate":0.666667,"avgChangeRate":0.265429},{"month":12,"riseRate":0.666667,"avgChangeRate":0.027237}],"exchange":"SEHK","name":"和黄医药","nameEN":"HUTCHMED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和黄医药,00013,和黄医药股票,和黄医药股票老虎,和黄医药股票老虎国际,和黄医药行情,和黄医药股票行情,和黄医药股价,和黄医药股市,和黄医药股票价格,和黄医药股票交易,和黄医药股票购买,和黄医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}